中高危非转移性肾癌术后靶向及免疫治疗的研究进展  

Research Progress of Postoperative Targeted and Immunotherapy for Medium to High Risk Non-metastatic Renal Cell Carcinoma

作　　者：邓继意 吴思承 林粮文 胡政邦 DENG Jiyi;WU Sicheng;LIN Liangwen;HU Zhengbang(Department of Urology,the First Affiliated Hospital of Nanchang University,Nanchang 330000,China;Department of Emergency,the First Affiliated Hospital of Nanchang University,Nanchang 330000,China)

机构地区：[1]南昌大学第一附属医院泌尿外科,南昌330000 [2]南昌大学第一附属医院急诊科,南昌330000

出　　处：《医学综述》2023年第11期2163-2169,共7页Medical Recapitulate

摘　　要：目前对于局限性及局部进展性中高危非转移性肾癌的治疗以手术为主,由于术后复发和转移的风险较高,因而术后辅助治疗具有一定的意义。对于肾切除术后辅助靶向治疗的适应证仍存在争议。现阶段,多项针对中高危非转移性肾癌术后靶向治疗的临床试验已经在世界各国开展,但获得总生存期或无疾病生存期阳性结果的研究却很少,而最近开展的高危非转移肾癌术后免疫治疗的研究取得了总生存期获益的阳性结果。随着免疫治疗的问世,基于肾癌术后的免疫治疗展现出广阔的价值前景,也让人们对于中高危非转移肾癌术后靶向及免疫治疗有了新期望。The current treatment for limited and locally progressive medium to high risk non-metastatic renal cell cancer is mainly surgery,and postoperative adjuvant therapy has certain significance because of the high risk of recurrence and metastasis after surgery.The indications for adjuvant targeted therapy after nephrectomy are still controversial.At this stage,several clinical trials for postoperative targeted therapy for medium to high risk non-metastatic renal cell cancer have been conducted worldwide,but few studies have obtained positive results for overall survival or disease-free survival,while the recently conducted study of postoperative immunotherapy for high risk non-metastatic renal cell cancer has achieved positive results for overall survival benefit.With the introduction of immunotherapy,postoperative immunotherapy for renal cell cancer has shown a broad value prospect and has raised new expectations for targeted and immunotherapy after surgery for intermediate to high risk non-metastatic renal cell cancer.

关 键 词：肾癌 靶向治疗 免疫治疗 免疫检查点抑制剂 总生存期 无病生存期 

分 类 号：R737.11[医药卫生—肿瘤]